Lung Cancer Actionable Panel

Test Code
SLS160001
Book Now

What is the Lung Cancer Actionable Panel?

This panel evaluates mutations involved in lung cancer in 7 genes using DNA sequencing and fusions in 6 genes using RNA sequencing; it also tests for PDL-1 expression (22C3 antibody), a marker used to assess eligibility for immunotherapy.

Genes Covered/ No. of Genes/ Biomarkers Covered: SNVs, InDels, and CNVs in 7 genes (DNA sequencing); Fusions in 6 genes (RNA sequencing); PDL-1 22C3 (Dako)

Who Is This Test For?

Patients with advanced or metastatic lung cancer who are being considered for both targeted therapies and immunotherapy.

Key Features

  • Covers 11 key genes in major lung cancer pathways
  • Detects mutations in 7 genes using DNA sequencing and fusions in 6 genes using RNA sequencing
  • Assesses PD-L1 expression (22C3 antibody clone) for immunotherapy eligibility

Clinical Applications

  • Identifies candidates for EGFR/ALK-targeted therapies and immune checkpoint inhibitors
  • Evaluates PD-L1 status to support use of PD-1/PD-L1-based immunotherapies

Lung Cancers

Contact Us